Model of Short and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A

Conclusions: The model suggests that prophylaxis treatment of HA with emicizumab can result in a lower number of bleeding events as well as delayed onset of arthropathy and inhibitor development. Findings indicate that prophylaxis with emicizumab leads to better patient outcomes and has a lower financial impact from the US societal perspective.DisclosuresMahajerin: Genentech Inc.: Consultancy. Zhou: Analysis Group, Inc.: Employment; Celgene Corporation: Research Funding. Raimundo: Genentech Inc: Employment, Other: Ownership interests PLC. Patel: Genentech Inc: Employment. Han: Analysis Group Inc.: Research Funding. Ji: Analysis Group Inc.: Research Funding. Zhong: Analysis Group Inc.: Research Funding. Betts: Analysis Group Inc.: Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Mahajerin, A., Zhou, Z.-Y., Raimundo, K., Patel, A., Han, S., Ji, Y., Zhong, J., Betts, K. Tags: 901. Health Services Research-Non-Malignant Conditions: Poster II Source Type: research